Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency.

Sheridan DA, Bridge SH, Crossey MM, Felmlee DJ, Thomas HC, Neely RD, Taylor-Robinson SD, Bassendine MF.

Metab Brain Dis. 2014 Sep;29(3):625-34. doi: 10.1007/s11011-014-9520-9. Epub 2014 Mar 12.

PMID:
24615429
2.

Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial.

Sheridan DA, Bridge SH, Crossey MM, Felmlee DJ, Fenwick FI, Thomas HC, Neely RD, Taylor-Robinson SD, Bassendine MF.

Liver Int. 2014 May;34(5):737-47. doi: 10.1111/liv.12316. Epub 2013 Oct 14.

PMID:
24118830
3.

Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.

Bard JM, Ose L, Hagen E, Duriez P, Pfister P, Fruchart JC, Dallongeville J.

Am J Cardiol. 1995 Jul 13;76(2):65A-70A.

PMID:
7604802
4.

Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b.

Atsukawa M, Tsubota A, Kondo C, Itokawa N, Narahara Y, Nakatsuka K, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Kanazawa H, Sakamoto C.

J Gastroenterol Hepatol. 2013 Jan;28(1):51-6. doi: 10.1111/j.1440-1746.2012.07267.x.

PMID:
22989264
5.

Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients.

Milazzo L, Meroni L, Galazzi M, Cesari M, Caramma I, Marchetti G, Galli M, Antinori S.

J Viral Hepat. 2009 Jul;16(7):479-84. doi: 10.1111/j.1365-2893.2009.01104.x. Epub 2009 Feb 8.

PMID:
19215577
6.

Depressive and anxiety disorders in chronic hepatitis C patients: reliability and validity of the Patient Health Questionnaire.

Navinés R, Castellví P, Moreno-España J, Gimenez D, Udina M, Cañizares S, Diez-Quevedo C, Valdés M, Solà R, Martín-Santos R.

J Affect Disord. 2012 May;138(3):343-51. doi: 10.1016/j.jad.2012.01.018. Epub 2012 Feb 10.

PMID:
22326842
7.

Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.

Broyles FE, Walden CE, Hunninghake DB, Hill-Williams D, Knopp RH.

Am J Cardiol. 1995 Jul 13;76(2):129A-135A.

PMID:
7604788
8.

Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity.

Deterding K, Grüner N, Buggisch P, Galle PR, Spengler U, Hinrichsen H, Berg T, Potthoff A, Grohennig A, Koch A, Diepolder H, Lüth S, Feyerabend S, Jung MC, Rogalska-Taranta M, Schlaphoff V, Cornberg M, Manns MP, Wedemeyer H, Wiegand J; Hep-Net Acute HCV-III Study Group.

Eur J Gastroenterol Hepatol. 2016 Feb;28(2):187-92. doi: 10.1097/MEG.0000000000000517.

PMID:
26575158
9.

[Variability of the hypolipidemic action of simvastatin and fluvastatin in patients with primary hyperlipoproteinemia].

Tvorogova MG, Susekov AV, Semenova OA, Kukharchuk VV, Titov VN.

Ter Arkh. 1998;70(12):8-13. Russian.

PMID:
10067240
10.

Fluvastatin inhibits hepatitis C replication in humans.

Bader T, Fazili J, Madhoun M, Aston C, Hughes D, Rizvi S, Seres K, Hasan M.

Am J Gastroenterol. 2008 Jun;103(6):1383-9. doi: 10.1111/j.1572-0241.2008.01876.x. Epub 2008 Apr 14.

PMID:
18410471
11.

Depression and protective factors of mental health in people with hepatitis C: a questionnaire survey.

Erim Y, Tagay S, Beckmann M, Bein S, Cicinnati V, Beckebaum S, Senf W, Schlaak JF.

Int J Nurs Stud. 2010 Mar;47(3):342-9. doi: 10.1016/j.ijnurstu.2009.08.002. Epub 2009 Sep 19.

PMID:
19766994
12.

Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study.

Donnelly LA, Palmer CN, Whitley AL, Lang CC, Doney AS, Morris AD, Donnan PT.

Pharmacogenet Genomics. 2008 Apr;18(4):279-87. doi: 10.1097/FPC.0b013e3282f60aad.

PMID:
18334912
13.

Beneficial effects of fluvastatin on progressive renal allograft dysfunction.

Konstadinidou I, Boletis JN, Perrea D, Triantafyllou A, Filiopoulos V, Stamataki E, Kostakis A, Stathakis ChP.

Transplant Proc. 2003 Jun;35(4):1364-7.

PMID:
12826160
14.

Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia.

Tomlinson B, Mak TW, Tsui JY, Woo J, Shek CC, Critchley JA, Masarei JR.

Am J Cardiol. 1995 Jul 13;76(2):136A-139A.

PMID:
7604789
15.

Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency.

Lintott CJ, Scott RS, Bremer JM, Shand BI.

Am J Cardiol. 1995 Jul 13;76(2):97A-101A.

PMID:
7604809
16.

Role of statins in the treatment of chronic hepatitis C virus infection.

Abd-Eldaem AA, Azmy MK, Ahmad YK, Badr GA, Houssein MA, El-Dahshan T.

J Egypt Soc Parasitol. 2012 Dec;42(3):535-40.

PMID:
23469629
17.

Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.

Insull W Jr, Black D, Dujovne C, Hosking JD, Hunninghake D, Keilson L, Knopp R, McKenney J, Stein E, Troendle AJ.

Arch Intern Med. 1994 Nov 14;154(21):2449-55.

PMID:
7979841
18.

Elderly patients with hypercholesterolaemia: a double-blind study of the efficacy, safety and tolerability of fluvastatin.

Lye M, Valacio R, Reckless JP, Ghosh AK, Findlay IN, Ghosh MK, Passmore AP, Fulcher RA.

Coron Artery Dis. 1998;9(9):583-90.

PMID:
9861520
19.

Fluvastatin and low-density lipoprotein oxidation in hypercholesterolemic renal transplant patients.

Martínez-Castelao A, Grinyó JM, Fiol C, Castiñeiras MJ, Hurtado I, Gil-Vernet S, Serón D, Porta I, Miñarro A, Villarroya A, Alsina J.

Kidney Int Suppl. 1999 Jul;71:S231-4.

PMID:
10412785

Supplemental Content

Support Center